Outcomes after intravenous thrombolysis in women versus men
| Outcome | No. (%) of patients | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI)* | P value | |
| Women (n=529) | Men (n=881) | |||||
| Primary outcomes | ||||||
| mRS 3–6 at 3 months | 243 (45.9) | 327 (37.1) | 1.44 (1.16 to 1.79) | 0.001 | 1.01 (0.75 to 1.37) | 0.95 |
| Safety outcomes | ||||||
| SICH (SITS-MOST) | 12 (2.4) | 15 (1.7) | 1.45 (0.69 to 3.07) | 0.33 | 1.26 (0.50 to 3.21) | 0.63 |
| SICH (NINDS) | 35 (6.5) | 43 (4.8) | 1.15 (0.66 to 2.00) | 0.62 | 0.89 (0.51 to 1.55) | 0.67 |
| SICH (ECASS II) | 22 (4.1) | 32 (3.6) | 1.38 (0.87 to 2.18) | 0.17 | 0.82 (0.42 to 1.61) | 0.56 |
| Mortality at 7 days | 32 (5.9) | 43 (4.8) | 1.25 (0.78 to 2.00) | 0.35 | 0.94 (0.51 to 1.71) | 0.83 |
| Mortality at 3 months | 60 (11.3) | 81 (9.2) | 1.26 (0.88 to 1.79) | 0.20 | 0.79 (0.50 to 1.26) | 0.32 |
*Adjusted baseline variables: age, diastolic blood pressure, current smoking, hypertension, diabetes mellitus, atrial fibrillation, antihypertensive agents before stroke, stroke-to-needle time, stroke-to-visit time, stroke-to-imaging time, National Institute of Health Stroke Scale (NIHSS) on admission and Trial of Org 10172 in Acute Stroke Treatment (TOAST) types.
ECASS II, second European–Australasian acute stroke study; mRS, modified Rankin Scale; NINDS, National Institute of Neurological Disorders and Stroke; SICH, symptomatic intracranial haemorrhage; SITS-MOST, safe implementation of treatments in stroke-monitoring study.